[Skip to Content]
[Skip to Content Landing]
Views 24,448
Citations 0
September 13, 2019

Redefining Heart Failure With a Reduced Ejection Fraction

Author Affiliations
  • 1Department of Medicine, University of Mississippi Medical Center, Jackson
  • 2Berlin-Brandenburg Center for Regenerative Therapies, Berlin, Germany
  • 3Department of Cardiology, German Center for Cardiovascular Research at Berlin, Charite Universitatsmedizin Berlin, Berlin, Germany
  • 4Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas
  • 5Imperial College, London, United Kingdom
JAMA. Published online September 13, 2019. doi:10.1001/jama.2019.15600

The current management of patients with chronic heart failure depends on the noninvasive measurement of left ventricular ejection fraction (LVEF). In patients with an LVEF of 40% or lower, large-scale randomized clinical trials have demonstrated the benefits of inhibitors of the renin-angiotensin system, sympathetic nervous system, aldosterone, and neprilysin in reducing the risk of cardiovascular death and hospitalization for heart failure. Because these trials only enrolled patients with an LVEF of 40% or lower, a value of 40% has been used to define patients with heart failure and a reduced ejection fraction (HFrEF) for the past 30 years. Current guidelines strongly recommend the use of combination treatment with neurohormonal antagonists for patients with HFrEF.1 By contrast, there are no evidence-based recommendations concerning the treatment of patients with LVEF greater than 40%, who have been conventionally referred to as having heart failure with a preserved ejection fraction (HFpEF). This lack of guidance is a concern because such patients now represent a majority of those with heart failure in the general community, particularly among women.2

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words